Skip to content

Deutetrabenazine

VMAT2 inhibitor • Brands: Austedo

Last reviewed: 2025-09-26

General information

Indicated for: Tardive dyskinesia; chorea associated with Huntington disease.

Dosing & forms

  • Forms/strengths: —
  • Frequency: —
  • Food: —
  • Typical range: 24–48 mg/day

Mechanism (brief)

VMAT2 inhibitor that reduces presynaptic dopamine packaging.

Metabolism & Half‑life

  • Metabolism: CYP2D6 to active metabolites.
  • Half‑life: ~9–10 h.

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

  • Mood/depression assessment — Baseline and each visit
  • QT risk assessment in susceptible patients — As indicated

Sources